CAS |
71939-50-9 |
Chinese Name |
双氢青蒿素 |
English Name |
Dihydroartemisinin |
Synonym |
Artenimol;β-Dihydroartemisinin;Dihydroqinghaosu |
Unit |
Bottle |
Purity |
HPLC≥98% |
Molecular Formula |
C15H24O5 |
Molecular Weight |
284.35 |
Appearance |
White to off-white solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO≥10mg/ml |
MDL |
MFCD00274495 |
InChIKey |
BJDCWCLMFKKGEE-ISOSDAIHSA-N |
InChI |
InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1 |
PubChem CID |
3000518 |
SMILES |
O[C@@H]1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1 |
Description |
Dihydroartemisin is an effective antimalarial compound. Dihydroartemisini can inhibit NF- κ B activation to induce autophagy and apoptosis. |
Target Point |
Parasite;NF-κB |
Passage |
Anti-infection |
IC50 |
33.6 ± 6.8 mmol/l(BxPC-3 cells) ; 49.9± 7.0 mmol/l(AsPC-1 cells)[4] |
Data Literature Source |
[1]. Hu W, et al. Dihydroartemisinin induces autophagy by suppressing NF-κB activation. Cancer Lett. 2014 Feb 28;343(2):239-48.
[2]. Li YJ, et al. Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-κB in Eca109 and Ec9706 esophageal cancer cells. Cell Physiol Biochem. 2014;33(5):1527-36.
[3]. Li HJ, et al. Dihydroartemisinin-praziquantel combinations and multiple doses of dihydroartemisinin in the treatment of Schistosoma japonicum in experimentally infected mice. Ann Trop Med Parasitol. 2011 Jun;105(4):329-33
[4]. Chen H, Sun B, Pan S, Jiang H, Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs. 2009 Feb;20(2):131-40. |
Specification |
50mg 10mM*1mL (in DMSO) 100mg |